

**Committee on Science, Space, and Technology**

**U.S. House of Representatives**

Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: <i>T. Celeste Napier</i>		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No <input checked="" type="checkbox"/>
3. Are you testifying on behalf of an entity that is not a government entity?	Yes	No <input checked="" type="checkbox"/>
4. Other than yourself, please list which entity or entities you are representing:		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2010:  <i>See attached</i>		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity(ies) you are representing:		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2010, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:		

I certify that the above information is true and correct.

Signature: *T. Celeste Napier*

Date: *09/16/13*

**Federal Grants  
October 2010 to present**

**T. Celeste Napier, Ph.D.**

“Cortical pathophysiology in cocaine self-administering HIV-1 transgenic rats”  
R21 DA033882  
National Institute on Drug Abuse \$275,000 2012-2014  
XiuTi Hu, M.D., Ph.D., Principal Investigator  
T. Celeste Napier, Ph.D., Principal Investigator

“A novel rodent model of dopamine agonist-induced impulsive control disorders”  
R21 NS074014  
National Institute of Neurological Disorders and Stroke \$275,000 2011-2013  
T. Celeste Napier, Ph.D., Principal Investigator

Chicago Developmental Center for AIDS Research (D-CFAR) \$3,500,000 2009-2014  
NIH multiple institutes (#P30 AI 082151)  
Alan Landay, Ph.D., Principal Director  
T. Celeste Napier, Ph.D., HIV and Addiction Research Emphasis Leader

A-START R03 (#DA026723) \$200,000 2010-2012  
“Protective pathways against Meth abuse and HIV neuropathogenesis”  
National Institute on Drug Abuse  
Lena Al-Harhi, Ph.D., Principal Investigator (P.I.)  
T. Celeste Napier, Ph.D., Co-Investigator (Co-I)

A-START R03 (#DA026746)  
“Chronic cocaine exposure & HIV-1 Tat: Dysregulation of the medial prefrontal cortex”  
National Institute on Drug Abuse \$200,000 2009-2011  
Xiu-Ti Hu, M.D., Ph.D., P.I.  
T. Celeste Napier, Ph.D.; Co-I.

Small Business Innovation Research (SBIR; #MH084365) \$100,000 2009-2010  
“Indolobenzox and thiazepines as atypical antipsychotic agents”  
National Institute for Mental Health  
Parthasarathi Rajagopalan, Ph.D.; P.I.  
T. Celeste Napier, Ph.D.; Co-I

Individual National Research Service Award F31  
National Institute for Drug Abuse (USPHSG #DA024923)  
“5HT receptors, neuronal plasticity, and meth-induced place preference”  
TDC: \$75,298 Dates: 01/01/09-12/31/11  
Steven M. Graves, Trainee, Principal Investigator  
T. Celeste Napier, Ph.D., Sponsor

Individual National Research Service Award F31  
National Institute for Drug Abuse (USPHSG #DA0331231)  
“Role of D3 receptors in drug-induced impulsivity in a rat model of Parkinson’s disease”  
TDC: \$126,696 Dates: 08/01/12-07/31/15  
Stephanie E. Tedford, Trainee, Principal Investigator  
T. Celeste Napier, Ph.D., Sponsor

Individual National Research Service Award F31  
National Institute for Drug Abuse (USPHSG #DA033206)  
“Pathophysiological Effects of Cocaine/HIV-1 Tat on the Medial Prefrontal Cortex”  
TDC: \$124,800 Dates: 12/01/11-11/30/14  
Wesley N. Wayman, Trainee, Principal Investigator  
XiuTi Hu, MD, PhD, Sponsor  
T. Celeste Napier, Ph.D., Co-Sponsor